<DOC>
	<DOCNO>NCT01037998</DOCNO>
	<brief_summary>Iressa [ epidermal growth factor tyrosine kinase inhibitor ( EGFR-TKI ) ] report activity Non-small-cell Lung Cancer ( NSCLC ) fail previous chemotherapy . UFUR find anti-angiogenesis effect long term treatment give . Combination EGFR-TKI anti-angiogenesis agent novel treatment .</brief_summary>
	<brief_title>UFUR ( Tegafur/Uracil ) Plus Iressa Non-small-cell Lung Cancer</brief_title>
	<detailed_description>Iressa selective epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR-TKI ) . It orally active agent advance non-small-cell lung cancer ( NSCLC ) fail previous platinum-based regimen taxane treatment . UFUR ( Tegafur/Uracil ) effective agent chemo-na√Øve NSCLC . It anti-angiogenesis effect use long-term low dose treatment . Present phase II randomize clinical trial design answer whether add oral anti-angiogenesis agent ( UFUR ) , low toxicity profile long term use , EGFR-TKI ( Iressa ) could increase patient survival response rate .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Histologic cytological diagnosis NSCLC fail previous platinumbased taxanes chemotherapy . No prior radiotherapy measurable lesion ( ) . Performance status 0 3 Zubrod scale . ( Reference 1 ) Clinically measurable disease , define bidimensionally measurable lesion clearly define margin xray , scan , physical examination . Lesions serve measurable disease must least 1 cm 1 cm , define CT scan , MRI , chest xray . Informed consent patient . Males females 18 year age old . If female : childbearing potential either terminate surgery , radiation , menopause , attenuate use approve contraceptive method ( intrauterine contraceptive device [ IUD ] , birth control pill , barrier device ) three month trial . Active infection ( discretion investigator ) . Inadequate liver function ( total bilirubin &gt; 1.5 time normal range ) ; alanine transaminase ( ALT ) aspartate transaminase ( AST ) great 5 time normal . Inadequate renal function ( creatinine &gt; 2.0 mg/dL ) . Breast feeding . Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) Concomitant myelosuppressive radiotherapy , chemotherapy , hormonal therapy , immunotherapy allow except palliative radiation nonmeasurable lesion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>adenocarcinoma</keyword>
	<keyword>non-small-cell lung cancer</keyword>
	<keyword>gefitinib</keyword>
	<keyword>UFUR</keyword>
</DOC>